Novartis AG Net Profit Margin 2010-2023 | NVS

Current and historical net profit margin for Novartis AG (NVS) from 2010 to 2023. Net profit margin can be defined as net Income as a portion of total sales revenue. Novartis AG net profit margin for the three months ending December 31, 2023 was .
Novartis AG Net Profit Margin Historical Data
Date TTM Revenue TTM Net Income Net Margin
2023-12-31 $46.66B $14.85B 31.83%
2023-09-30 $46.02B $7.84B 17.03%
2023-06-30 $44.71B $7.65B 17.11%
2023-03-31 $43.86B $7.03B 16.02%
2022-12-31 $43.46B $6.96B 16.00%
2022-09-30 $50.20B $21.80B 43.42%
2022-06-30 $52.79B $22.98B 43.54%
2022-03-31 $53.00B $24.18B 45.63%
2021-12-31 $52.88B $24.02B 45.43%
2021-09-30 $56.14B $9.81B 17.47%
2021-06-30 $51.56B $8.98B 17.43%
2021-03-31 $49.88B $7.96B 15.95%
2020-12-31 $49.90B $8.07B 16.18%
2020-09-30 $45.83B $7.10B 15.50%
2020-06-30 $49.53B $7.21B 14.56%
2020-03-31 $49.93B $12.14B 24.32%
2019-12-31 $48.68B $11.73B 24.10%
2019-09-30 $47.86B $11.80B 24.66%
2019-06-30 $46.76B $11.38B 24.34%
2019-03-31 $46.39B $12.35B 26.63%
2018-12-31 $46.10B $12.61B 27.36%
2018-09-30 $47.37B $13.39B 28.27%
2018-06-30 $48.67B $13.85B 28.46%
2018-03-31 $49.51B $8.06B 16.28%
2017-12-31 $50.14B $7.70B 15.36%
2017-09-30 $49.58B $6.68B 13.48%
2017-06-30 $49.23B $6.54B 13.29%
2017-03-31 $49.41B $6.37B 12.89%
2016-12-31 $49.44B $6.71B 13.58%
2016-09-30 $49.63B $6.81B 13.72%
2016-06-30 $49.78B $6.76B 13.57%
2016-03-31 $50.00B $6.79B 13.58%
2015-12-31 $50.39B $17.78B 35.29%
2015-09-30 $50.94B $18.22B 35.77%
2015-06-30 $51.75B $19.56B 37.79%
2015-03-31 $52.81B $20.27B 38.39%
2014-12-31 $53.63B $10.21B 19.04%
2014-09-30 $52.60B $10.75B 20.43%
2014-06-30 $52.21B $9.76B 18.69%
2014-03-31 $51.54B $9.72B 18.85%
2013-12-31 $52.72B $9.18B 17.40%
2013-09-30 $49.87B $9.13B 18.31%
2013-06-30 $51.00B $9.29B 18.21%
2013-03-31 $52.26B $9.42B 18.03%
2012-12-31 $51.97B $9.27B 17.84%
2012-09-30 $57.49B $8.29B 14.41%
2012-06-30 $58.48B $8.36B 14.30%
2012-03-31 $59.07B $8.42B 14.25%
2011-12-31 $59.38B $8.94B 15.06%
2011-09-30 $58.84B $10.11B 17.18%
2011-06-30 $56.63B $9.92B 17.51%
2011-03-31 $53.43B $9.63B 18.03%
2010-12-31 $51.56B $9.79B 18.99%
2010-09-30 $50.24B $9.93B 19.76%
2010-06-30 $48.71B $9.75B 20.02%
2010-03-31 $47.53B $9.37B 19.71%
2009-12-31 $45.10B $8.40B 18.62%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $200.005B $45.440B
Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy, and xRNA. Novartis efforts to strengthen its wide and deep oncology portfolio by developing breakthrough treatments. Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio. In March 2015, Novartis acquired certain oncology products and pipeline compounds from Glaxo. In exchange, it sold its non-influenza Vaccines business to Glaxo. Also, the company has spun off the Alcon business into a separate company. In January 2015, Novartis divested its Animal Health division to Lilly. In July 2015, the company divested its influenza vaccines business to CSL Limited. Novartis has also acquired The Medicines Company, adding Leqvio, to its portfolio. Novartis sold its investment in Roche.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $690.114B 114.92
Novo Nordisk (NVO) Denmark $550.665B 45.36
Johnson & Johnson (JNJ) United States $356.431B 14.14
Merck (MRK) United States $318.604B 83.85
AbbVie (ABBV) United States $294.653B 14.98
AstraZeneca (AZN) United Kingdom $212.533B 18.83
Pfizer (PFE) United States $147.226B 14.21
Sanofi (SNY) $117.121B 10.55
Innoviva (INVA) United States $0.945B 6.67